STSeung-Jea Tahk

Seung-Jea Tahk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Seung-Jea Tahk has a total of 381 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Five‐Year Clinical Outcomes of Biodegradable Versus Durable Polymer Drug‐Eluting Stents: A Propensity Score‐Matched Analysis of 4394 Patients

    by Yangyoun Lee, Hong‐Seok Lim, Kyoung‐Woo Seo, Hyoung‐Mo Yang, So‐Yeon Choi, Seung‐Jea Tahk, Myeong‐Ho Yoon

    Background: Biodegradable‐polymer (BP) drug‐eluting stents (DES) were developed to mitigate potential late adverse events related to persistent durable polymers in durable‐polymer (DP) DES; however, contemporary long‐term real‐world comparative data remain limited. Aims: We aimed to compare the 5‐year clinical outcomes of contemporary BP‐DES and DP‐DES in patients undergoing routine percutaneous coronary intervention (PCI). Methods: We analyzed consecutive patients undergoing PCI with second‐generation or newer DES at a single institution (2010–2021). Propensity scores were estimated using prespecified clinical, angiographic, and procedural covariates, and 1:1 nearest‐neighbor matching was performed. The primary endpoint was 5‐year target lesion failure (TLF: cardiac death, target vessel myocardial infarction [TV‐MI], or clinically driven target lesion revascularization [TLR]). Key secondary endpoints were 1‐year TLF, all‐cause mortality, and ARC‐2 definite or probable stent thrombosis. A prespecified 1‐year landmark analysis evaluated outcomes from 0 to 1 and 1 to 5 years. Results: After matching, 2197 pairs (4394 patients) were included. At 5 years, TLF occurred in 7.9% of BP‐DES and 7.9% of DP‐DES patients (HR 1.01, 95% CI 0.81–1.26; p = 0.936). No statistically significant differences were observed in secondary endpoints, including 1‐year TLF, individual TLF components, all‐cause mortality, or ARC‐2 definite or probable stent thrombosis. All‐cause mortality at 5 years was similar between groups (7.1% vs. 8.2%; HR 0.87, 95% CI 0.69–1.09; p = 0.213); however, in the 1–5‐year landmark period, mortality was numerically lower with BP‐DES (HR 0.73, 95% CI 0.53–1.00; nominal p = 0.047). No significant treatment‐by‐subgroup interactions were observed. Conclusions: In routine PCI using second‐generation or newer DES, BP‐DES and DP‐DES demonstrated comparable 5‐year TLF. The potential late survival signal with BP‐DES is hypothesis‐generating and should be interpreted cautiously given the observational design.


  • Open Access

    Osfit™, a Novel Stent Designed for the Treatment of Coronary Ostial Lesions: Initial Clinical Experience and Intravascular Ultrasound Evaluation

    by Kyoung-Woo Seo, Seung-Jea Tahk, Hyoung-Mo Yang, Hong-Seok Lim, Myeong-Ho Yoon, So-Yeon Choi

    Seo KW, et al. Korean Circ J. 2025 Feb;55:e30. https://doi.org/10.4070/kcj.2024.0256


  • Open Access

    Discordance Between Angiographic Assessment and Fractional Flow Reserve or Intravascular Ultrasound in Intermediate Coronary Lesions: A Post-hoc Analysis of the FLAVOUR Trial

    by Jung-Hee Lee, Sung Gyun Ahn, Ho Sung Jeon, Young Jin Youn, Jinlong Zhang, Xinyang Hu, Jian’aN Wang, Joo Myung Lee, Joo-Yong Hahn, Chang-Wook Nam, et al.

    Lee JH, et al. Korean Circ J. 2024 Jun;54:e69. https://doi.org/10.4070/kcj.2024.0046


  • Clinical Outcomes of Deferred Lesions by IVUS Versus FFR-Guided Treatment Decision

    by Joo Myung Lee, Hangyul Kim, David Hong, Doyeon Hwang, Jinlong Zhang, Xinyang Hu, Jun Jiang, Chang-Wook Nam, Joon-Hyung Doh, Bong-Ki Lee, et al.

    BACKGROUND: There are limited data regarding the safety of deferral of percutaneous coronary intervention based on intravascular ultrasound (IVUS) findings. The current study sought to compare the prognosis between deferred lesions based on IVUS and fractional flow reserve (FFR)–guided treatment decision. METHODS: This study is a post hoc analysis of the FLAVOUR randomized trial (Fractional Flow Reserve and Intravascular Ultrasound for Clinical Outcomes in Patients With Intermediate Stenosis) that compared 2-year clinical outcomes between IVUS- and FFR-guided treatment decision on intermediate coronary artery lesions using predefined criteria. In both IVUS and FFR groups, vessels were classified into deferred or revascularized vessels, and patients were classified as those with or without deferred lesions. Vessel-oriented composite outcomes (cardiac death, target vessel myocardial infarction, or target vessel revascularization) in deferred vessels and patient-oriented composite outcomes (death, myocardial infarction, or any revascularization) in patients with deferred lesions were compared between the IVUS and FFR groups. RESULTS: A total of 1682 patients and 1820 vessels were analyzed, of which 922 patients and 989 vessels were deferred. At 2 years, there was no difference in the cumulative incidence of vessel-oriented composite outcomes in deferred vessels between IVUS (n=375) and FFR (n=614) groups (3.8% versus 4.1%; hazard ratio, 0.91 [95% CI, 0.47–1.75]; P =0.77). The risk of vessel-oriented composite outcomes was comparable between deferred and revascularized vessels following treatment decision by IVUS (3.8% versus 3.5%; hazard ratio, 1.09 [95% CI, 0.54–2.19]; P =0.81) and FFR (4.1% versus 3.6%; hazard ratio, 1.14 [95% CI, 0.56–2.32]; P =0.72). In comparison of patient-oriented composite outcomes in patients with deferred lesions, there was no significant difference between the IVUS (n=357) and FFR (n=565) groups (6.2% versus 5.9%; hazard ratio, 1.05 [95% CI, 0.61–1.80]; P =0.86). CONCLUSIONS: In patients with intermediate coronary artery stenosis, deferral of percutaneous coronary intervention based on IVUS-guided treatment decision showed comparable risk of clinical events with FFR-guided treatment decision. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02673424.


  • Open Access

    Sustained beneficial effect of β-blockers on clinical outcomes after discontinuation in patients with ST elevation myocardial infarction

    by Jin-Sun Park, Kyoung-Woo Seo, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Seung-Jea Tahk, Joon-Han Shin

    Our previous study demonstrated that beneficial effect of β-blockers on clinical outcomes in patients with ST elevation myocardial infarction (STEMI). In clinical practice, β-blocker treatment is occasionally discontinued due to their side effect. The purpose of this study is to assess the impact of discontinuation of β-blockers on long-term clinical outcomes in patients with STEMI. We analyzed the data and clinical outcomes of 901 patients (716 males, 58 ± 13-year-old) STEMI patients who underwent successful primary percutaneous coronary intervention. At discharge of index STEMI, 598 patients were treated with β-blockers (491 males, 56 ± 12-year-old). After more than 1-month β-blocker treatment, β-blockers were stopped in 188 patients for any reason. We classified patients into continuation of β-blockers (410 patients, 56 ± 12-year-old) and discontinuation of β-blockers groups (188 patients, 57 ± 11-year-old) according to discontinuation of β-blockers. Occurrence of major adverse cardiovascular events (MACEs; death, recurrent MI and target vessel revascularization) during up to 10 years of follow-up was evaluated. Mean follow-up month was 56 ± 28 month. In 132 patients (22%), MACEs were occurred. The MACE-free survival rates in the 2 groups were not statistically different (log-rank P = .461). Adjusted hazard ratio (HR) of discontinuation of β-blockers for MACEs was 1.006 (95% confidence interval (CI) 0.701–1.445, P = .973; all cause of death, HR = 0.942, 95% CI = 0.547–1.622, P = .828; recurrent MI, HR = 0.476, 95% CI = 0.179–1.262, P = .136; target vessel revascularization, HR = 1.417, 95% CI = 0.865–2.321, P = .166). The MACE-free survival and survival rates of the non β-blockers treatment group was significantly worse than the discontinuation of β-blockers group (log-rank P = .003 and < 0.001, respectively). This study demonstrated that discontinuation of β-blockers was not associated with adverse cardiovascular outcomes after STEMI. The beneficial effect of β-blockers on clinical outcomes may persist in patients with initial β-blockers treatment at index STEMI.


  • Open Access

    Effect of Stenting Strategy on the Outcome in Patients with Non-Left Main Bifurcation Lesions

    by Yongwhan Lim, Min Chul Kim, Youngkeun Ahn, Doo Sun Sim, Young Joon Hong, Ju Han Kim, Myung Ho Jeong, Hyeon-Cheol Gwon, Hyo-Soo Kim, Seung Woon Rha, et al.

    Previous studies have not compared outcomes between different percutaneous coronary intervention (PCI) strategies and lesion locations in non-left main (LM) bifurcation lesions. We enrolled 2044 patients from a multicenter registry with an LAD bifurcation lesion (n = 1551) or non-LAD bifurcation lesion (n = 493). The primary outcome was target lesion failure (TLF), a composite of cardiac death, myocardial infarction, and target lesion revascularization (TLR). During a median follow-up period of 38 months, non-LAD bifurcation lesions treated with the two-stent strategy, compared with the one-stent strategy, were associated with more frequent TLF (20.7% vs. 6.3%, p < 0.01), TLR (16.7% vs. 4.7%, p < 0.01), and target vessel revascularization (TVR; 18.2% vs. 6.3%, p < 0.01). There was no significant difference in outcome among LAD bifurcation lesions treated with different PCI strategies. The two-stent strategy was associated with a higher risk of TLF (adjusted HR 4.34, CI 1.93–9.76, p < 0.01), TLR (adjusted HR 4.30, CI 1.64–11.27, p < 0.01), and TVR (adjusted HR 5.07, CI 1.69–9.74, p < 0.01) in the non-LAD bifurcation lesions. The planned one-stent strategy is preferable to the two-stent strategy for the treatment of non-LAD bifurcation lesions.


  • Open Access

    Five-year clinical outcomes of the first Korean-made sirolimus-eluting coronary stent with abluminal biodegradable polymer

    by Kyoung-Woo Seo, Hyoung-Mo Yang, Junghan Yoon, Hyo-Soo Kim, Kiyuk Chang, Hong-Seok Lim, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Seung-Hwan Lee, et al.

    This study evaluated the 5-year clinical outcomes of the Genoss DES, the first Korean-made sirolimus-eluting coronary stent with abluminal biodegradable polymer. We previously conducted the first-in-patient prospective, multicenter, randomized trial with a 1:1 ratio of patients using the Genoss DES and Promus Element stents; the angiographic and clinical outcomes of the Genoss DES stent were comparable to those of the Promus Element stent. The primary endpoint was major adverse cardiac events (MACE), which was a composite of death, myocardial infarction (MI), and target lesion revascularization (TLR) at 5 years. We enrolled 38 patients in the Genoss DES group and 39 in the Promus Element group. Thirty-eight patients (100%) from the Genoss DES group and 38 (97.4%) from the Promus Element group were followed up at 5 years. The rates of MACE (5.3% vs 12.8%, P = .431), death (5.3% vs 10.3%, P = .675), TLR (2.6% vs 2.6%, P = 1.000), and target vessel revascularization (TVR) (7.9% vs 2.6%, P = .358) at 5 years did not differ significantly between the groups. No TLR or target vessel revascularization was reported from years 1 to 5 after the index procedure, and no MI or stent thrombosis occurred in either group during 5 years. The biodegradable polymer Genoss DES and durable polymer Promus Element stents showed comparable low rates of MACE at the 5-year clinical follow-up.


  • Open Access

    Lipid-Core Plaque Assessed by Near-Infrared Spectroscopy and Procedure Related Microvascular Injury

    by Hyoung-Mo Yang, Myeong-Ho Yoon, Hong-Seok Lim, Kyoung-Woo Seo, Byoung-Joo Choi, So-Yeon Choi, Gyo-Seung Hwang, Seung-Jea Tahk

    Yang HM, et al. Korean Circ J. 2018 Aug;49:e100. https://doi.org/10.4070/kcj.2019.0072


  • Open Access

    Ischemia-based Coronary Revascularization: Beyond Anatomy and Fractional Flow Reserve

    by Hong-Seok Lim, Kyoung-Woo Seo, Myeong-Ho Yoon, Hyoung-Mo Yang, Seung-Jea Tahk

    Lim HS, et al. Korean Circ J. 2016 Sep;48:e1. https://doi.org/10.4070/kcj.2017.0177


  • Open Access

    Extrinsic Compression of the Left Main Coronary Artery by a Huge Aortic Arch Aneurysm Mimicking Acute Coronary Syndrome

    by Jeoung-Sook Shin, So-Yeon Choi, Sang Hyun Lim, Jun Ho Jung, Doo-Kyoung Kang, Seung-Jea Tahk

    Shin JS, et al. Korean Circ J. 2016 Sep;48:e13. https://doi.org/10.4070/kcj.2017.0313